Abstract:Objective: This study explored the value of circulating tumor cells (CTC) detected by chromosome 8 centromere probe in diagnosis of non-small cell lung cancer (NSCLC) as well as correlation between CTC counts and clinical pathological characteristics. Methods: We collected 136 patients with newly diagnosed NSCLC (101 males and 35 females, age ranged from 34 to 79 years), 149 patients with non-malignant pulmonary diseases (103 males and 46 females, age ranged from 24 to 80 years) and 32 healthy volunteers (5 males and 27 females, age ranged from 24 to 42 years). Detection was performed using an epithelial cell adhesion molecule-independent strategy that combined immunocytochemistry staining (ICC) of CD(45) and fluorescence in situ hybridization detection (FISH) with chromosome 8 centromere probe (CEP8). CTC was defined as 4',6-diamidino-2-phenylindole (DAPI) positive, CD(45) negative and CEP8 more than 2 positive points. Quantitative data were reported as x±s and Mann Whitney test was used to compare them. Measurement data were analyzed as contingency tables and Pearson chi-squared test was used. P values of less than 0.05 were considered statistically significant. Results: CTCs were detected in 114 patients (83.8%) with NSCLC, 35 patients (23.5%) with non-malignant pulmonary diseases (P<0.000 1) and 5 volunteers (15.6%). CTC counts in NSCLC patients were (5.98±0.64) per 3.2 ml and (0.60±0.13) per 3.2 ml (P<0.000 1). A receiver operating characteristic curve (ROC) analysis showed similar capability of CTC count, with CEA, in discriminating NSCLC and non-malignant diseases with an area under ROC curve of 0.854 (95% confidence interval: 0.808-0.900, P<0.001). Cutoff of 2 circulating tumor cells per 3.2 ml peripheral blood gave the highest Youden Index of 0.614 in diagnosis of NSCLC with sensitivity of 72.1% (98/136) and specificity of 89.3% (133/149). When patients with CTC≥2/3.2 ml peripheral blood or serum CEA≥5 ng/ml were considered as having NSCLC, sensitivity and specificity of this combined test were 87.5% (119/136) and 85.9% (128/149), with a higher Youden Index of 0.734. No correlation was observed between positive rate of CTC (rate of patients with CTC≥2/3.2 ml peripheral blood) and age, gender, smoking status, pathologic types, and clinical stages. Conclusions: CTC counts detected by CD(45)-FISH is higher in NSCLC patients than in non-malignant disease patients. CTC≥2/3.2 ml peripheral blood is valuable in discriminating NSCLC from nonmalignant diseases, which can be more accurate when combined with CEA.

Predictive and Prognostic Significance of Circulating Endothelial Cells in Advanced Non-Small Cell Lung Cancer Patients

Prognostic value of circulating endothelial cells in non-small cell lung cancer patients: a systematic review and meta-analysis.

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

Dynamic Changes of Circulating Tumor Cells During Chemotherapy As a Prognostic Factor in Patients with Advanced Lung Cancer.

Predictive value of circulating endothelial cells for efficacy of chemotherapy with Rh-endostatin in non-small cell lung cancer

Level of Activated Circulating Endothelial Cells to Predict Progression-Free Survival of Anlotinib Treatment in Patients with NSCLC: Analysis on ALTER-0303 Study.

High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.

Circulating Tumor-Derived Endothelial Cells: an Effective Biomarker for Breast Cancer Screening and Prognosis Prediction

Circulating tumor cells ( CTCs )/circulating tumor endothelial cells ( CTECs ) and their subtypes in small cell lung cancer: Predictors for response and prognosis

Clinical significance of circulating tumour cells and tumour marker detection in the chemotherapeutic evaluation of advanced colorectal cancer

Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer

Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer

Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma.

Effect of Circulating Tumor Cells Combined with Negative Enrichment and CD45-FISH Identification in Diagnosis, Therapy Monitoring and Prognosis of Primary Lung Cancer

Predictive value of circulating tumor cell counts during the treatment of cancer: interactions with the blood microenvironment

Clinical significance of detecting circulating tumor cells in patients with esophageal squamous cell carcinoma by EpCAM‑independent enrichment and immunostaining‑fluorescence in situ hybridization

Circulating tumor cells predict survival benefit from chemotherapy in patients with lung cancer.

The Role of Serum Carcinoembryonic Antigen in Predicting Responses to Chemotherapy and Survival in Patients with Non-Small Cell Lung Cancer

Preliminary Investigation Of The Value Of The Change Of Circulating Tumor Cells In Predicting The Efficacy And Prognosis Against Advanced Non-Small Cell Lung Cancer

Circulating Tumor Cells (CTC): Assessment of Treatment Efficacy in Metastatic Breast Cancer (MBC)

Prognostic value of circulating tumor cells detected with the CellSearch system in esophageal cancer patients: a systematic review and meta-analysis